Clinuvel Pharmaceuticals (CUV) H2 2024 earnings summary

Executive summary

• Achieved record revenue and profit, marking the eighth consecutive annual profit and seventh consecutive annual dividend.

• Strategic focus on reinvesting profits into R&D&I, diversification, and pipeline development, while maintaining profitability.

• Expansion in headcount and leadership, including new CFO, COO, and other key roles, strengthening operational foundation.

• Expansion strategy includes entry into new jurisdictions and product lines.

Financial highlights

• Total revenue increased 15% year-over-year, reaching $95.3m, driven by demand for Scenesse in Europe and North America.

• Net profit after tax rose 16% to $35.6m; EBIT margin reached 53%, and net profit after tax margin was 37%.

• Cash reserves increased 17% to $183.9m, with total assets at $231.1m and a $27m increase in cash.

• Basic EPS rose to $0.72, up 15% year-over-year.

• Declared a fully franked dividend of $0.05 per share and invested nearly $750,000 in share buybacks.

Outlook and guidance

• No formal guidance provided, but strong balance sheet and cash reserves enable pursuit of organic and inorganic growth opportunities.

• Next three-year expenses plan to be finalized in Q4 2024 and revealed in H1 2025.

• Focus on R&D for new formulations, products, and indications, with continued disciplined capital deployment.

• On track with self-imposed objectives for 2024; new objectives to be presented at the AGM.